Zibotentan (BioDeep_00000185099)

   

human metabolite blood metabolite


代谢物信息卡片


trans,trans-2(4-Methoxyphenyl)-4-(1-3-benzodiazol-5-yl)-1-(dibutylaminocarbonylmethyl)pyrrolidine-3-carboxylic acid

化学式: C19H16N6O4S (424.0953696)
中文名称: Zibotentan
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4
InChI: InChI=1S/C19H16N6O4S/c1-12-10-21-17(19(23-12)28-2)25-30(26,27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H,1-2H3,(H,21,25)

描述信息

C28313 - Endothelin Receptor Antagonist
Zibotentan (ZD4054) is a potent, selective and orally active endothelin A (ETA) receptor antagonist with a Ki of 13 nM. Zibotentan has no inhibitory effect on ETB. Zibotentan has anticancer effects and can be used for castration-resistant prostate cancer (CRPC) research[1][2].

同义名列表

7 个代谢物同义名

trans,trans-2(4-Methoxyphenyl)-4-(1-3-benzodiazol-5-yl)-1-(dibutylaminocarbonylmethyl)pyrrolidine-3-carboxylic acid; N-(3-Methoxy-5-methyl-1,2-dihydropyrazin-2-ylidene)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulphonamide; N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide; Zibotentan (ZD4054); ZD-4054ZIBOTENTAN; Zibotentan; ZD4054



数据库引用编号

9 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Edward P Stern, Lauren V Host, Ivy Wanjiku, K Jane Escott, Peter S Gilmour, Rachel Ochiel, Robert Unwin, Aine Burns, Voon H Ong, Helen Cadiou, Aidan G O'Keeffe, Christopher P Denton. Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial. Arthritis research & therapy. 2022 06; 24(1):130. doi: 10.1186/s13075-022-02818-6. [PMID: 35650639]
  • Weisong Shen, Hongqing Xi, Chenyang Li, Shibo Bian, Haidong Cheng, Jianxin Cui, Ning Wang, Bo Wei, Xiaohui Huang, Lin Chen. Endothelin-A receptor in gastric cancer and enhanced antitumor activity of trastuzumab in combination with the endothelin-A receptor antagonist ZD4054. Annals of the New York Academy of Sciences. 2019 07; 1448(1):30-41. doi: 10.1111/nyas.14053. [PMID: 30937921]
  • Terry W Moody, Irene Ramos-Alvarez, Paula Moreno, Samuel A Mantey, Lisa Ridnour, David Wink, Robert T Jensen. Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells. Peptides. 2017 04; 90(?):90-99. doi: 10.1016/j.peptides.2017.01.012. [PMID: 28153500]
  • Ping Qi, Ming Chen, Li-xiu Zhang, Rui-xia Song, Zhen-hua He, Zhi-ping Wang. A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer. PloS one. 2015; 10(7):e0133803. doi: 10.1371/journal.pone.0133803. [PMID: 26192308]
  • Jacqueline A Clarkson-Jones, Alison S J Kenyon, John Kemp, Eva M Lenz, Stuart D Oliver, Helen Swaisland. Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers. Xenobiotica; the fate of foreign compounds in biological systems. 2012 Apr; 42(4):363-71. doi: 10.3109/00498254.2011.624204. [PMID: 22014279]
  • J A Clarkson-Jones, A S J Kenyon, H K Tomkinson. The disposition and metabolism of zibotentan (ZD4054): an oral-specific endothelin A receptor antagonist in mice, rats and dogs. Xenobiotica; the fate of foreign compounds in biological systems. 2011 Sep; 41(9):784-96. doi: 10.3109/00498254.2011.562565. [PMID: 21657967]
  • Eva M Lenz, Alison Kenyon, Scott Martin, Dave Temesi, Jacqueline Clarkson-Jones, Helen Tomkinson. The metabolism of [14C]-zibotentan (ZD4054) in rat, dog and human, the loss of the radiolabel and the identification of an anomalous peak, derived from the animal feed. Journal of pharmaceutical and biomedical analysis. 2011 Jun; 55(3):500-17. doi: 10.1016/j.jpba.2011.02.005. [PMID: 21398067]
  • Helen Tomkinson, John Kemp, Stuart Oliver, Helen Swaisland, Maria Taboada, Thomas Morris. Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies. BMC clinical pharmacology. 2011 Mar; 11(?):3. doi: 10.1186/1472-6904-11-3. [PMID: 21414193]
  • M Ranson, R H Wilson, J M O'Sullivan, M Maruoka, A Yamaguchi, R A Cowan, J P Logue, H Tomkinson, N Tominaga, H Swaisland, S Oliver, M Usami. Pharmacokinetic and tolerability profile of once-daily zibotentan (ZD4054) in Japanese and Caucasian patients with hormone-resistant prostate cancer. International journal of clinical pharmacology and therapeutics. 2010 Nov; 48(11):708-17. doi: 10.5414/cpp48708. [PMID: 20979929]
  • H C Swaisland, S D Oliver, T Morris, H K Jones, A Bakhtyari, A Mackey, A D McCormick, D Slamon, J A Hargreaves, A Millar, M T Taboada. In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers. Xenobiotica; the fate of foreign compounds in biological systems. 2009 Jun; 39(6):444-56. doi: 10.1080/00498250902810944. [PMID: 19480550]
  • C D Morris, A Rose, J Curwen, A M Hughes, D J Wilson, D J Webb. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. British journal of cancer. 2005 Jun; 92(12):2148-52. doi: 10.1038/sj.bjc.6602676. [PMID: 15956965]